you you for morning Good Thank Tiffany. all us and joining thank today.
marked begin and a The modified we year. With clinical regulatory of are by second gene dosing end progress to through we quarter biologic-based our of XXXX programs, our on across advancing of period focus milestones, patients end these novel to ophthalmic a which therapy expect toward the dedicated platforms of continued year. this strategic and the
III trials We Phase initiate OCUXXX the plans. track proposed adult III discussions subject XXXX, to of with outcomes and FDA are early near on ongoing Phase of Phase XXXX, trials I/II on end to trial
update study We also this OCUXXX for quarter. anticipate clinical a results
Investigational trials OCUXXX We geographic OCUXXXST of for end atrophy new XXXX. and the I/II drug Phase by respectively. were cleared applications disease, to and initiate by plan FDA Stargardt for
half of initiate product trial and second in mean late-stage programs This in Neocart, Phase XXXX. regenerative for to clinical planning cell also in have therapy are We therapies would candidate, would XXXX. the Ocugen the cell III gene
with platform, funding OCUXXX and patient-centric conserve secure vaccine support mucosal government our having their non-dilutive submitted pertinent capital for inhaled In advance obtain to working we develop to a effort agenda to our agencies proposals novel our an and multiple vaccine are to discussions series. have
approach wide. address diseases modifier retinal treat potential therapy one first-in-class caused unique by unmatched remains retinal to genes gene-agnostic the inherited has with mutations in This to diseases gene Our multiple multiple industry product.
to single potential gene from therapy that retinal are a gene patients to the rare host and expand wider build unable to a on suffering population of is Our treat of its address. replacement diseases goal therapies innovation of
medical and In we Bioinformational our for Ophthamology to attendance in in Vision conferences. modified researchers honored were therapy for gene present and and the Research the the platform in quarter, of preeminent and mechanism second basis scientific professionals detail to at action Association
we to educate opportunities potential innovative differentiation advance will identify clinical agenda, and continue we and to of our gene to As approach the stakeholders secure therapy. on benefits this
the encouraging our for between suffering In ages of all in early of ongoing these the a III defined April, FDA, Phase viable I/II gene we patients dose alternative to efficacy we We therapy modified believe feedback trial positive with study initiate our to to results of and traditional open the announced clinical this from OCUXXX from Enrolment preliminary and from clinical preliminary compelling end this with this increasing LCA is adult positive in our adults aim near afflicted XX. trial or X label the the multi-center subjects RP. XXXX. patients study, Phase potential safety diseases. to population supports children and for be to treatments from findings ranging year Pending
built upon our meet execute strategy have Ocugen needed to options therapy upside most RP our may that to the continue patients XXXX our and In other modified progressing ophthalmic LCA. vast successful the additional and, to that market providing will bring for OCUXXX we’ll for XXX,XXX We footprint realization for estimated the patients. from a it suffer importantly, in conditions. gene continue develop and goals, We parallel, of desperately alone to address with medical by treatment of a comprehensive that goal shareholders significant commercial U.S. programs hold critical believe these need
the and small of sight variety life. to million Dry and is results investigating modifier option oxidative of to lack that we a a all eye potential U.S. people develop candidate of burdensome that approximately can complement in companies therapy and among With impacts AMD, elderly irreversible XXX believe again severely degeneration conditions the stress, one-time independence option OCUXXX of neurodegenerative of metabolism, nearly our a Dry patients. therapies functional prevalent age-related four macular activation. AMD; people treatment loss are large offer novel dry of targets however, the working biotechnology AMD to one most worldwide. our provide we diseases lipid for million our populations hallmark less dry for leading for quality in affecting are XX OCUXXX, A including gene inflammation,
targets of per current factor, and The has care requires complement multiple standard reported injections the only effects. year, side
are medical We because significant clinical the unmet year excited to Phase trial I/II global this initiate of the need.
maintain nuclear the designation that that survival believe a as regulators retinal such OCUXXXST by novel such related activity dystrophy, onto are AAV RAR delivery causing disrupted cell A. harnessing Moving the orphan and hormone networks. receptors orphan Stargardt modulate to diseases for nuclear one-time platform physiological functions to we that of are modified from extremely can the retinal an disease receptors can cone-rod OCUXXXST, leverages there gene mutations. and homeostasis therapy to ABCAX-associated metabolism, we are address receive RPXX, is modulate hormone diverse treatment by master pleased photoreceptor regulating disease, cell by and Nuclear as options. deployed which activity We drug power receptors, as gene no inflammation, development of delivery currently FDA cell hormone that and receptor gene help treatments phototransduction, maintenance, develop for
company potential a a help for delivery global our to neutralization invasive distinct trials to titre mucosal mucosal a and vaccines multiple vaccine-induced cross of Inhaled when for develop series major the in with our of less Pending have effector high serve current remedy IND trial application health which government funding, an administration. a next represent vaccines demonstrated candidate vaccines, submit preclinical turning and maximize with mechanism to efforts broader durability XXXX. compared product Now that via intends generation responses. for section inhalation to opportunity intramuscular challenges a could patients in superior
of systemic and one similar shown year of durable immune for mucosal amongst improved the vaccination vector world. to administration presents traditionally administration potential compliance traditional wider the one the antibodies, intramuscular Clinical dose using populations with antibodies adoption, underserved and developing to response inhaled studies Greater and a vaccines. particularly compared fifth throughout have of up ease
to lack marginal limited Current COVID-XX durability are of transmission. and vaccines by ability prevent
flu protect OCUXXX, inhaled COVID-XX, and commitment to are As a seasonal includes of this inhaled flu address vaccination that a vaccine barriers we vaccine, developing reduce inhaled to OCUXXX, to one up biovalent vaccine. COVID-XX series shared a against OCUXXX OCUXXX, novel designed The is on potential a our vaccine seasonal vaccine, platform transmission quadrivalent and inhaled part and to protect widespread to a durability biovalent with COVID-XX quadrivalent year. against platform based combination variants new
vaccine this our ongoing maintain development We anticipate our respective pending information on support with series. our later further health officials across diverse engaging value, government critically resources agencies federal optimize non-dilutive maintain to and To to agencies funding the dialogue our public and of year. pursue and development the status has of programs OCUXXX team receiving shareholder with and been request needed an
program Earlier to on us a were and information requested this chemistry, related additional controls. putting they notified OCUXXX the year, hold manufacturing FDA that and our
as potential FDA with hold patients. the treatment and to targets diabetic the are has and treatment and macular action oxidation mechanism therapies We of existing to pathways trial for to causative OCUXXX Phase a of the in all edema works believe the XXXX. be angiogenesis, QX working compared with We multiple better initiated such I and release distinct expect to to inflammation, offer
end on Manufacturing of combines processing Neocart bioengineering second our cell facility the with in target autologous that Phase cartilage plans to subjects Phase articular cell regenerative the to in III-ready enhance is XXXX as advancement be for process. of planned. completed company and in initiate repair to trial technology III XXXX. Neocart is the half by therapy novel cartilage defects The construction
will vaccines to platform to next reach across our completing all and believe enhancing to BLAs dedicated gene in cell therapies, technologies, objectives are strategies highly are and Ocugen with first-in-class total enable the file to therapies three years. we the We value stated five planning milestones
second overview now financial provide an for results of will XXXX. quarter key the I
XXXX. the were as well $X.X a as the Covaxin, included and associated expenses second ended of payment the of million the short to compared on research $XX.X of fixed disposal assets. for related result quarter Our advanced the the non-recurring, the non-cash of XXXX million of supply of quarter of expense million asset XX, development term for a the This loss June $X as impairment for
a to expenses the Net ended or share million compared administrative XX, $XX.X share net quarter approximately of for loss quarter quarter June XXXX. net million loss June second of net loss per the XXXX loss million were $X.XX $XX.X for compared quarter second was for the million approximately per of ended XXXX. and $XX.X for the XXXX $X.XX General XX, to or $X.X
as Our million June XX, $XX.X million cash, XXXX XX, cash XXXX. investments to $XX.X December of equivalents and compared totaled as of
and for R&D. of being are offering expenses, working $XX.X capital used In offering for million stock public gross May, corporate we shares from expenditures, million. of XX the general of general proceeds a purposes, closed proceeds and common capital, Net administrative
exploring We to continuously capital and focused corporate partnerships for seeking vaccines. on will our working gene are be out funding opportunities for increase therapies and non-dilutive
update concludes the back to quarter. That my you. for Tiffany,
